F. Croon-de Boer

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

A. Kater, C. Mellink, M. Levin, 2018, Blood advances.

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

A. Kater, Jean Y. J. Wang, M. V. van Oers, 2015, Leukemia & lymphoma.

[Skin abnormalities as first sign of Waldenström macroglobulinaemia].

F. Croon-de Boer, E. R. Lonnee, M. F. Visser, 2010, Nederlands tijdschrift voor geneeskunde.

Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma

P. V. van Hagen, D. Paridaens, V. Dalm, 2018, Orbit.

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

K. de Heer, K. Nasserinejad, P. Sonneveld, 2021, Blood.

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

A. Kater, Jean Y. J. Wang, M. V. van Oers, 2015, Leukemia & lymphoma.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.